Literature DB >> 22202071

Histamine receptor subtypes: a century of rational drug design.

Miriam Walter1, Holger Stark.   

Abstract

Histamine plays an important role as neurotransmitter and chemical mediator in multiple physiological and pathophysiological processes in central and peripheral tissues. In the last century the extensive study of its actions in the human body, resulted in the identification of four G protein-coupled receptor (GPCR) subtypes (H1R-H4R), mediating numerous effects. The successful application of H1R and H2R antagonists/inverse agonists in the treatment of allergic conditions and gastric ulcer proved that these two receptors are excellent drug targets. Ligands for H3R are currently in advanced stages of clinical development for a broad spectrum of mainly central diseases (e.g. narcolepsy, Alzheimer's disease, epilepsy and schizophrenia). Meanwhile, preclinical research in the H4R field, focused on inflammatory and immunological processes, led to the evaluation of the first H4R-targeting clinical candidates. Drug development for each histamine receptor subtype will be discussed with a special focus on H3R and H4R ligands.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22202071     DOI: 10.2741/s279

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  16 in total

1.  Bodilisant-a novel fluorescent, highly affine histamine h3 receptor ligand.

Authors:  Miriam Tomasch; J Stephan Schwed; Alexander Paulke; Holger Stark
Journal:  ACS Med Chem Lett       Date:  2012-12-12       Impact factor: 4.345

2.  Histamine H4 receptor signalling in tongue cancer and its potential role in oral carcinogenesis - a short report.

Authors:  Abdelhakim Salem; Rabeia Almahmoudi; Dyah Listyarifah; Maria Siponen; Katariina Maaninka; Ahmed Al-Samadi; Tuula Salo; Kari K Eklund
Journal:  Cell Oncol (Dordr)       Date:  2017-06-26       Impact factor: 6.730

Review 3.  Mast Cell Activation Syndrome in COVID-19 and Female Reproductive Function: Theoretical Background vs. Accumulating Clinical Evidence.

Authors:  Dariusz Szukiewicz; Piotr Wojdasiewicz; Mateusz Watroba; Grzegorz Szewczyk
Journal:  J Immunol Res       Date:  2022-06-22       Impact factor: 4.493

4.  KSK-74: Dual Histamine H3 and Sigma-2 Receptor Ligand with Anti-Obesity Potential.

Authors:  Kamil Mika; Małgorzata Szafarz; Monika Zadrożna; Barbara Nowak; Marek Bednarski; Katarzyna Szczepańska; Krzysztof Pociecha; Monika Kubacka; Noemi Nicosia; Izabela Juda; Katarzyna Kieć-Kononowicz; Magdalena Kotańska
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

5.  Influence of the novel histamine H₃ receptor antagonist ST1283 on voluntary alcohol consumption and ethanol-induced place preference in mice.

Authors:  Amine Bahi; Bassem Sadek; Stephan J Schwed; Miriam Walter; Holger Stark
Journal:  Psychopharmacology (Berl)       Date:  2013-03-09       Impact factor: 4.530

Review 6.  Histamine pharmacology: from Sir Henry Dale to the 21st century.

Authors:  Ekaterini Tiligada; Madeleine Ennis
Journal:  Br J Pharmacol       Date:  2018-12-02       Impact factor: 8.739

7.  Stromal interaction molecule 1 (STIM1) and Orai1 mediate histamine-evoked calcium entry and nuclear factor of activated T-cells (NFAT) signaling in human umbilical vein endothelial cells.

Authors:  Meng-Hua Zhou; Hongying Zheng; Hongjiang Si; Yixin Jin; Jasmine M Peng; Lian He; Yubin Zhou; Carlos Muñoz-Garay; David C Zawieja; Lih Kuo; Xu Peng; Shenyuan L Zhang
Journal:  J Biol Chem       Date:  2014-09-04       Impact factor: 5.157

8.  Novel chalcone-based fluorescent human histamine h(3) receptor ligands as pharmacological tools.

Authors:  Miriam Tomasch; J Stephan Schwed; Lilia Weizel; Holger Stark
Journal:  Front Syst Neurosci       Date:  2012-03-26

9.  Identification of histamine receptor subtypes in skeletal myogenesis.

Authors:  Yan Chen; Vasily Stegaev; Vesa-Petteri Kouri; Tarvo Sillat; Paul L Chazot; Holger Stark; Jian Guo Wen; Yrjö T Konttinen
Journal:  Mol Med Rep       Date:  2014-12-10       Impact factor: 2.952

Review 10.  Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration.

Authors:  Rona R Ramsay; Magdalena Majekova; Milagros Medina; Massimo Valoti
Journal:  Front Neurosci       Date:  2016-08-22       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.